{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:47:31Z","timestamp":1769600851498,"version":"3.49.0"},"reference-count":27,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Octapharma"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Hematology"],"published-print":{"date-parts":[[2018,4,21]]},"DOI":"10.1080\/10245332.2017.1385892","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T06:47:54Z","timestamp":1507790874000},"page":"242-247","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Tolerability and safety of the intravenous immunoglobulin octagam<sup>\u00ae<\/sup>10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8838-6707","authenticated-orcid":false,"given":"Stefan","family":"Wietek","sequence":"first","affiliation":[{"name":"Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Svorc","sequence":"additional","affiliation":[{"name":"Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Debes","sequence":"additional","affiliation":[{"name":"Octapharma GmbH, Langenfeld, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tor-Einar","family":"Svae","sequence":"additional","affiliation":[{"name":"Octapharma Inc., Hoboken, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1370-4"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04876.x"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302984"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225565"},{"key":"CIT0005","doi-asserted-by":"crossref","unstructured":"Octapharma Ltd. Octagam 10% solution for infusion: summary of product characteristics [Internet]. 2016 Apr 12 [cited 2016 Oct 3]. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/24831","DOI":"10.1016\/S1365-6937(16)30279-9"},{"key":"CIT0006","unstructured":"Octapharma USA Inc. Octagam 10% [immune globulin intravenous (human)] liquid solution for intravenous administration: US prescribing information [Internet]. 2014 Jul [cited 2016 Oct 3]. Available from: http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/ucm064946.pdf"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.5414\/CP202782"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1179\/102453310X12719010991867"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.30"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1160\/TH03-10-0650"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1179\/102453309X439773"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096600"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04389.x"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01476.x"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2013.05.004"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1449"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12663"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2010.484419"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2005.11.015"},{"key":"CIT0020","unstructured":"European Medicines Agency. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) [Internet]. 2010 Oct 21 [cited 2015 Oct 6]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/12\/WC500099542.pdf"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2012.01648.x"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.11part2.78S"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.09.2214"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01502.x"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2014.04.002"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1159\/000354893"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2011.11.004"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10245332.2017.1385892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10245332.2017.1385892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T10:01:32Z","timestamp":1659607292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10245332.2017.1385892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4,21]]}},"alternative-id":["10.1080\/10245332.2017.1385892"],"URL":"https:\/\/doi.org\/10.1080\/10245332.2017.1385892","relation":{},"ISSN":["1607-8454"],"issn-type":[{"value":"1607-8454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-10-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}